In SPMS patients (cohort 2), sNfL levels were at 4.8 ± 2.7 (IQR 1.8 – 7.4 pg/ml) 4 weeks after NAT and remained stable at the individual level during the 16 weeks follow up period (Figure 4B). The gene discussed is BRD2; the disease is secondary progressive multiple sclerosis.